Using blood samples to identify pathogens in infective endocarditis patients
Accuracy of Metagenomic Blood Sampling to Identify Pathogen in Infective Endocarditis Patients
Queen Mary University of London · NCT06309680
This study is testing a new way to quickly identify the germs causing infective endocarditis in patients to help doctors give better-targeted treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Queen Mary University of London (other) |
| Locations | 1 site (London) |
| Trial ID | NCT06309680 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on improving the treatment of infective endocarditis by accurately identifying the causative organisms through clinical metagenomics. Traditional blood culture methods can take up to five days and may fail to identify pathogens in 18% of cases, leading to broader and potentially more toxic antibiotic treatments. By utilizing advanced sequencing technology, the study aims to provide rapid and precise identification of pathogens, which can enhance targeted antimicrobial therapy and improve patient outcomes. The study is conducted at Barts Heart Centre, one of the largest cardiac centers globally, which manages a significant number of infective endocarditis cases.
Who should consider this trial
Good fit: Ideal candidates include patients over 18 years old with possible or confirmed infective endocarditis referred to the BHC Endocarditis MDT.
Not a fit: Patients whose diagnosis of endocarditis is rejected by the MDT or those who have received intravenous antibiotics for more than 7 days prior to study entry may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and safer treatment options for patients with infective endocarditis.
How similar studies have performed: While traditional blood culture methods have limitations, the use of clinical metagenomics is a novel approach that has shown promise in preliminary studies but is still being evaluated for widespread clinical application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with possible or confirmed IE referred to BHC Endocarditis MDT * Age \>18 * Able and willing to give informed consent Exclusion Criteria: * Patients whose diagnosis of endocarditis is "rejected" by the MDT. If this occurs after entry to the study samples will be discarded and the patient informed. * Patients who have been treated with intravenous antibiotics for more than 7 days at the time of study entry.
Where this trial is running
London
- St Bartholomew's Hospital. West Smithfield — London, United Kingdom (RECRUITING)
Study contacts
- Study coordinator: Simon Woldman
- Email: simon.woldman@nhs.net
- Phone: 07901009105
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Infective Endocarditis, endocarditis